Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leela Barham

Latest From Leela Barham

Pressure Mounts For Agreement On New UK Voluntary Pricing Scheme

With the clock ticking on UK drug pricing negotiations, it is still unclear whether even high-level terms of a new voluntary deal will be agreed in time.

Europe United Kingdom

Industry Calls For Reform of England’s Unused Innovative Medicines Fund

The pharmaceutical industry says financial uncertainties are a key reason why the English Innovative Medicines Fund (IMF) – offering the potential for time-limited funding for promising non-cancer treatments where benefits are uncertain at launch - has still not been used a year after it was put in place. Industry wants the National Health Service to share the financial risk of taking part in the fund.

Europe United Kingdom

Ipsen Accuses Government Of Backward Step With Proposed Changes to Statutory Pricing Scheme

Ipsen and other experts have criticized proposals from the UK government on changes to the statutory scheme for the pricing of branded medicines. Plans for differential rebates are seen as too complex, meaning their impact is difficult to predict and they could end up costing the government more.

Europe United Kingdom

Almost 3,000 Patients Treated Under UK’s Early Access To Medicines Scheme

Data provided to the Pink Sheet under freedom of information requests show the scale of patient access that has been delivered under the UK’s scheme for early access to products that have yet to receive a marketing authorization.

Europe United Kingdom

Shortfall In Rebates Could Stymie UK Generics Industry’s Call For Exemptions Under New Pricing Scheme

The UK’s generics and biosimilars industry body, the BGMA, has set out what it wants from the new drug pricing scheme due to start up in January 2024. But a key request – exempting some branded generics and biosimilars from rebates - would leave a hole in the government’s finances.

Europe United Kingdom

UK Government And Industry Still Far Apart In Talks on New Pricing Scheme

The UK pharmaceutical industry association, the ABPI, says it and the government are still far from reaching a deal on a new voluntary pricing agreement and has suggested that a transition to the statutory scheme could be on the cards if an acceptable deal cannot be secured.

Europe United Kingdom
See All